GlassScriptPhysician profile
Rajesh Pandey
NPI 1144486200
$5,639.79
in general payments reported to CMS, 2019-2025
40 companies · $510 in 2025
The $510 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $790 · 2020: $760 · 2021: $881 · 2022: $959 · 2023: $958 · 2024: $781 · 2025: $510.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,249.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $762.51 | 2020-2025 | |
| Amgen INC. | $716.98 | 2019-2025 | Enbrel, Tavneos, Evenity |
| E.R. Squibb & Sons, L.L.C. | $639.00 | 2019-2025 | Orencia |
| Novartis Pharmaceuticals Corporation | $606.13 | 2021-2025 | |
| Janssen Biotech, INC. | $355.92 | 2019-2024 | Tremfya |
| Ucb, INC. | $299.61 | 2021-2025 | Cimzia, Bimzelx |
| Depuy Synthes Sales INC. | $241.21 | 2020-2022 | |
| Genzyme Corporation | $202.06 | 2019-2024 | |
| Intrinsic Therapeutics | $194.74 | 2022 | |
| Horizon Therapeutics Plc | $183.83 | 2019-2023 | Krystexxa |
| Pfizer INC. | $181.60 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.46 | 2022-2024 | Cyltezo |
| Janssen Pharmaceuticals, INC | $134.28 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $123.88 | 2021-2024 | |
| Genentech USA, INC. | $99.00 | 2020 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajesh Pandey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.